EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 182 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 2.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $110,000 | +1.9% | 1,936 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $108,000 | +10.2% | 1,936 | 0.0% | 0.00% | +33.3% |
| Q1 2019 | $98,000 | +25.6% | 1,936 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $78,000 | -27.8% | 1,936 | +23.9% | 0.00% | -25.0% |
| Q3 2018 | $108,000 | 0.0% | 1,562 | +9.2% | 0.00% | 0.0% |
| Q2 2018 | $108,000 | +44.0% | 1,430 | 0.0% | 0.00% | +33.3% |
| Q1 2018 | $75,000 | +17.2% | 1,430 | +20.4% | 0.00% | +50.0% |
| Q4 2017 | $64,000 | +10.3% | 1,188 | +22.7% | 0.00% | 0.0% |
| Q3 2017 | $58,000 | +7.4% | 968 | +41.9% | 0.00% | 0.0% |
| Q2 2017 | $54,000 | +107.7% | 682 | +121.4% | 0.00% | +100.0% |
| Q1 2017 | $26,000 | – | 308 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |